Boostrix + Placebo (Saline)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prevention of Infections With Bordetella Pertussis
Conditions
Prevention of Infections With Bordetella Pertussis
Trial Timeline
Aug 24, 2015 → Dec 15, 2016
NCT ID
NCT02555540About Boostrix + Placebo (Saline)
Boostrix + Placebo (Saline) is a approved stage product being developed by Novartis for Prevention of Infections With Bordetella Pertussis. The current trial status is completed. This product is registered under clinical trial identifier NCT02555540. Target conditions include Prevention of Infections With Bordetella Pertussis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02555540 | Approved | Completed |
Competing Products
20 competing products in Prevention of Infections With Bordetella Pertussis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| edoxaban + enoxaparin sodium | Daiichi Sankyo | Phase 3 | 77 |
| Mifepristone | Eli Lilly | Phase 2 | 52 |
| EXANTA | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Placebo | AstraZeneca | Phase 3 | 77 |
| PCV15 | Merck | Pre-clinical | 23 |
| Raltegravir | Merck | Approved | 85 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| V501 | Merck | Phase 3 | 77 |
| Zostavax | Merck | Phase 3 | 77 |
| V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 | Merck | Phase 3 | 77 |
| Letermovir + Placebo | Merck | Phase 3 | 77 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 85 |
| Enteric-coated mycophenolate sodium | Novartis | Phase 3 | 77 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 85 |
| rMenB+OMV NZ | Novartis | Phase 3 | 77 |
| Enteric-Coated Mycophenolate Sodium | Novartis | Phase 3 | 77 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml | Novartis | Phase 3 | 77 |
| Meningococcal C Conjugate Vaccine | Novartis | Phase 3 | 77 |